Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07416604 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
NCT07416604 is a Phase 3 study that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 360 participants.
The verdict
NCT07416604, a Phase 3 study, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.
Interventions
- DRUG Emicizumab
- COMBINATION_PRODUCT NXT007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2032-01-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07416604
The ClinicalTrials.gov registry entry for NCT07416604 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Emicizumab is the first listed.
NCT07416604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07416604 about?
NCT07416604 is a clinical study titled "A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A". The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia ...
What is the current status of trial NCT07416604?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2026-04-27. Estimated completion is 2032-01-29.
What interventions are being tested in trial NCT07416604?
The interventions under investigation include: Emicizumab (DRUG), NXT007 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07416604?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.